PRagmatic Trial Of Messaging to Providers About Treatment of Heart Failure in the Inpatient Setting

NACompletedINTERVENTIONAL
Enrollment

1,012

Participants

Timeline

Start Date

July 7, 2021

Primary Completion Date

December 14, 2022

Study Completion Date

June 30, 2023

Conditions
Heart Failure
Interventions
OTHER

Best practice alert for the notification of patient HFrEF and recommended evidence-based medical therapies (NO drugs are being administered in this trial)

Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction, most recent blood pressure and heart rate, most recent potassium and estimated glomerular filtration rate, and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.

Trial Locations (1)

06512

Yale New Haven Hospital, New Haven

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Yale University

OTHER